Thomas Tu

Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review

Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies

Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent

Mechanisms of HBV-induced hepatocellular carcinoma

Global burden of liver disease: 2023 update

Hepatitis B virus infection

Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer

HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant

Taming a beast: lessons from the domestication of hepatitis C virus

Hepatocellular Carcinoma

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1

Repurposing approved drugs on the pathway to novel therapies

Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells

Epidemiology and aetiology of hepatocellular carcinoma in Sub-Saharan Africa

HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon

Chronic viral hepatitis and its association with liver cancer

HBV DNA Integration: Molecular Mechanisms and Clinical Implications

Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection